WO2004101493A1 - カルバ糖アミン誘導体の酸付加塩 - Google Patents
カルバ糖アミン誘導体の酸付加塩 Download PDFInfo
- Publication number
- WO2004101493A1 WO2004101493A1 PCT/JP2004/007138 JP2004007138W WO2004101493A1 WO 2004101493 A1 WO2004101493 A1 WO 2004101493A1 JP 2004007138 W JP2004007138 W JP 2004007138W WO 2004101493 A1 WO2004101493 A1 WO 2004101493A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- added
- stirred
- mixture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel acid addition salt of a carbasaccharide amine derivative.
- the sugar dyslipidemia conventional G M 1 cancer Dario Sydow cis, ceramide lactoside libido cis, Morukio B's disease, Krabbe disease, Fabry disease, Gaucher disease, Tay- Sachs disease, Sandhoff disease, such as is known fucosidosis I have. These diseases are the result of mutations of various glycolytic enzymes. Among them, G M1 gangliosidosis, Morquio B disease, ceramide lactosidrividosis, Krabbe disease) is 3-galactosidase, and Gaucher disease is a disease resulting from mutation of ⁇ -dalcosidase and loss of enzyme activity. It is.
- a carbasaccharide amine derivative As a substance having a potential as a medicament for these diseases, a carbasaccharide amine derivative is known (WO 03/022797).
- Derivatives of carpasaccharides described in WO 03/022797 have the function of reducing the activity of mutated enzymes or restoring lost activity, but have extremely low water solubility and are used as pharmaceuticals That was not enough. Disclosure of the invention
- the present inventors have conducted intensive studies to solve the above problems, and as a result, have found an acid addition salt of a specific carbsaccharide amide derivative exhibiting a strong galactosidase inhibitory activity or a ⁇ -dalcosidase inhibitory activity, and this is an excellent aqueous solvent. Thus, the present invention has been completed.
- the present invention is as follows.
- R 1 and R 2 are each independently a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an acyl group, an aryl group which may have one or more of the following substituents (I) or ( ⁇ ). Or an aralkyl group, or R 1 and R together represent a substituent ( ⁇ )
- R 8 to R 12 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an acyl group, an aryl group, or an aralkyl group.
- R 1 and R are not both hydrogen atoms at the same time
- R 3 and R 7 each independently represent a hydroxyl group or a hydroxyl group having a substituent
- R 5 and R 6 each independently represent a hydrogen atom or a hydroxyl group or a hydroxyl group having a substituent
- R 1 and R 2 have the same meanings as in the above (1).
- R 1 and have the same meanings as in the above (1).
- a medicament comprising, as an active ingredient, the acid addition salt of a carbasaccharide amine derivative according to any one of (1) to (4).
- a method for producing an acid addition salt of a carpasaccharide amine derivative which comprises contacting a carbasaccharide amine derivative represented by the following general formula (1) with an acid in an aqueous solvent to form an acid addition salt. .
- R 8 to R 12 each independently represent an alkyl group, an alkenyl group, an alkyl group, an acyl group, an aryl group, or an aralkyl group.
- R 1 and R 2 are both hydrogen atoms at the same time.
- R 4 and R 7 each independently represent a hydroxyl group or a hydroxyl group having a substituent
- R 6 each independently represent a hydrogen atom or a hydroxyl group having a hydroxyl group or a substituent
- one of R 5 and R 6 is a hydrogen atom
- the other is hydroxyl or a hydroxyl group having a substituent.
- the present invention is an acid addition salt of a carbasaccharide amine derivative represented by the above general formula (1) (hereinafter, referred to as “the present substance”).
- R 1 and are each independently a hydrogen atom, one or more of the following substituents
- Residues commonly used in the field of organic chemistry to modify functional groups or protect side chains such as alkyl, aryl, or aralkyl, which may have (I) or (II), or R 1 and Represents a substituent ( ⁇ ).
- R 8 to R 12 are an alkyl group, an alkenyl group, an alkynyl group, an acyl group, an aryl group, Or an aralkyl group.
- R 1 and R 2 are not simultaneously hydrogen atoms.
- the alkyl group include a linear or branched alkyl group having from! To 30, preferably from 2 to 23 carbon atoms.
- the active ingredient is It is preferable that the structure can be an analog of glycosphingolipid.
- R 1 in the above general formula is particularly preferable. Most preferably, it has a linear alkyl group having 8 to 23 carbon atoms.
- those having a branch may have a substituent introduced into the alkyl group.
- the substituent include an alkoxy group, an aryloxy group, an amino group, a hydroxyl group and a silyl group. Is mentioned.
- a skeleton in which hydrogen bonded to the carbon of an alkyl group such as alkyl glycerol is replaced with a hydroxyl group and further, for example, an alkyl group having a straight chain (which may be a branched alkyl group) is an ether bond. (See the following formula (2)), etc. (in the following structural formula, ra independently represents an integer of 0 to 30).
- the alkenyl group and the alkynyl group preferably have 1 to 30, preferably 2 to 23 carbon atoms, and may have a plurality of double bonds and triple bonds between carbon atoms.
- the above-mentioned acyl group may be any group as long as it is generally a group represented by —CO—R, but has a carbon number of 1 to 30, preferably 2 to 23 in the entire acyl group.
- R is a group selected from the above-described alkyl group, alkenyl group, alkynyl group, aryl group and aralkyl group described below.
- the aryl group may be an aryl group having 6 to 22 carbon atoms, preferably 6 to 14 carbon atoms.
- an aromatic hydrocarbon residue such as a phenyl group or a naphthyl group, or an aromatic hydrocarbon residue in which a substituent such as an alkyl group or an acyl group is substituted with a hydrogen atom of an aromatic ring.
- a substituent such as an alkyl group or an acyl group is substituted with a hydrogen atom of an aromatic ring.
- a tolyl group for example, a tolyl group.
- the aralkyl group is a group having a general structure of Ar-(C) n -in which a hydrogen atom of an alkyl group is substituted by an aryl group, wherein n is preferably 1 to 30, and more preferably 2 to 23.
- Examples of such an aralkyl group include a benzyl group, a phenethyl group, and a -methylbenzyl group.
- alkyl group, alkenyl group, alkyl group, acyl group, aryl group or aralkyl group which may have (I) or ( ⁇ ) having the above substituents include the following compounds (A) to (D):
- Examples of the compound having a substituent ( ⁇ ) in which R 1 and R 2 are combined include the following compounds.
- R 13 to R 15 represent a hydrogen atom, an alkyl group having 0 to 30 carbon atoms, an alkenyl group, an alkynyl group, an acyl group, an aryl group, or an aralkyl group.
- R and R are a hydroxyl group or a hydroxyl group having a substituent, a hydroxyl group is particularly preferable.
- R 5 and R 6 when one of R 5 and R 6 is a hydroxyl group or a hydroxyl group having a substituent, the other represents a hydrogen atom. Neither is a hydroxyl group or a hydroxyl group having a substituent at the same time.
- R 5 and R 6 are each independently a hydrogen atom, a hydroxyl group or a hydroxyl group having a substituent, a hydroxyl group is particularly preferred.
- the substituent of the hydroxyl group includes an aralkyl group (benzyl group, phenyl group, ⁇ -methylbenzyl group, etc.), a silyl group (trimethinolesilinole group, triethylsilyl group, triisopropylsilyl (TIPS)) Group, t-butyldiphenylsilyl
- TDPS t-butyldimethylsilyl
- alkanoyl acetyl, butyryl, etc.
- aroyl benzoyl, toluoyl, naphthoyl, etc.
- alkoxyalkyl methyl
- a single substituent such as a methoxymethyl (MOM) group, an aralkyloxyalkyl group (a benzyloxymethyl (B0M) group, etc.) or an alkylidene group (methylidene group, Examples thereof include an ethylidene group), an isopropylidene group, and an aralkylidene group (eg, a benzylidene group).
- the MOM group is particularly preferable from the viewpoints of stability, ease of handling and elimination.
- the substance of the present invention is an acid addition salt of the compound represented by the above general formula (1).
- acid addition salts include, for example, inorganic acids (sulfuric acid, nitric acid, phosphoric acid, hydrohalic acid)
- the substance of the present invention is a carohydrate salt with an acid of a compound represented by the general formula (1), which is a kind of pseudo sugar
- the carbon number of the compound in the present specification is as follows according to the example of hexose. Described by the method shown in the general formula (3).
- the substance of the present invention is a salt of a substance having a high inhibitory activity on galactosidase or j3-dalcosidase derived from mammals, especially humans, it inhibits these enzymes particularly in vitro or in vivo (cells, tissues, etc.). And a drug based on such an enzyme inhibitory action or a drug for treating (treating or preventing) a disorder of glycolipid metabolism.
- the substance of the present invention when used as a medicine, has a much higher solubility in water-soluble solvents such as water than known free-type substances, so that the blood concentration can be increased and the dosage can be reduced. It is thought that it can be used, and various formulations can be easily prepared.
- the substance of the present invention can also be used for studying the pathology of diseases caused by mutations in galactosidase or ⁇ -dalcosidase.
- the inhibitory activity against j3 -galactosidase is as follows: ⁇ In a solution in which galatatosidase and a substrate are present,-Inhibiting activity in respect to dalcosidase is in a solution in which dalcosidase and a substrate are present The inhibitory activity can be calculated by comparing with the case where the substance of the present invention is not added.
- the substance of the present invention, the mammalian j3 - Garatatoshidaze or beta - relative activity Darukoshidaze is preferably in that salts of a substance having a 50% inhibitory concentration of less than 1 mol / 1 (IC 5 0 ), in particular IC 5. Is preferably less than 0.5 ⁇ mol / 1.
- the substance of the present invention is a compound represented by the general formula (1) obtained by the method described in International Publication WO 03/022797 or the synthesis route of FIG. 1 (for example, a compound represented by the general formula (1) 1A-2 or (1 ) 1B-2) in an aqueous solvent, for example, by reacting with 1 to 6 raol / 1 of the above exemplified acid (eg, hydrochloric acid, acetic acid, etc.). After the above reaction, it is preferably azeotroped with an organic solvent (eg, ethanol and toluene), The W residue can be obtained by dissolving in water and freeze-drying.
- an organic solvent eg, ethanol and toluene
- the medicament of the present invention may contain other components as long as it contains an effective amount of the substance of the present invention.
- the present medicament can be produced, for example, by combining the substance of the present invention with a pharmaceutically acceptable carrier.
- the carrier is not particularly limited, but includes, for example, excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, diluents, surfactants, and solvents for injections which are usually used in pharmaceuticals. And the like.
- the dosage form of the medicament of the present invention is not particularly limited and can be appropriately selected depending on the purpose of treatment. Specifically, tablets, pills, suspensions, emulsions, capsenoles, liquids, syrups, suppositories, injections , Granules, powders, lipolating agents, inhalable powders and the like.
- the medicament of the present invention can be orally or parenterally administered to mammals including humans.
- the timing of administration is not particularly limited, and the timing of administration can be appropriately selected according to the method of treating the target disease.
- the administration form is preferably determined according to the preparation form, the age and sex of the patient, other conditions, the degree of symptoms of the patient, and the like.
- the dose of the medicament of the present invention should be individually set according to the type of active ingredient, specific activity, the type and condition of the animal to be administered, the type of living tissue to be administered, its condition, and the like. Yes, but not particularly limited, it is generally possible to administer about 0.1 ⁇ g to 100 mg as an acid addition salt of the compound represented by the general formula (1) per day.
- the concentration of the active ingredient in the medicament of the present invention is appropriately selected depending on the usage, age and sex of the patient, degree of the disease, other conditions, and the like.
- the concentration of the medicament of the present invention as an active ingredient is preferably 0.001 to 5% (W / V).
- the medicament of the present invention when used as a liquid preparation for oral administration, it is preferably 0.01% (W / V) or more, and 0.03% to 0.2%.
- (W / V) is most preferable. In the case of injection for intramuscular or intravenous injection, it is preferably at least 0.01% (W / V), most preferably at least 0.03% ( ⁇ / V).
- the substance of the present invention has a specific and strong inhibitory activity against normal monogalactosidase or 3-gnorecosidase derived from a baby animal, and also has the activity of these enzymes reduced or lost in vivo.
- ⁇ -galacto It can be used for excellent treatment or prevention of glycolipid metabolism disorders based on mutations in the gene for the sidase or ⁇ -dalcosidase.
- FIG. 1 is a diagram showing a scheme for synthesizing the substance of the present invention.
- MOM represents a methoxymethyl group
- B0C represents a t-butoxycarpoyl group
- Ac represents an acetyl group
- Ph represents a phenyl group
- MS represents methanesulfonic acid.
- FIG. 2 is a graph showing neutral j3-galactosidase inhibitory activity of substances A-2 to 7 of the present invention.
- FIG. 3 is a diagram showing the neutralization) -galatatosidase inhibitory activity of the substances B-2 to 7 of the present invention.
- FIG. 4 is a diagram showing the acid-galactosidase inhibitory activity of the substances A-2 to 7 of the present invention.
- FIG. 5 is a graph showing the neutral i3-darcosidase inhibitory activity of substances A-2 to 7 of the present invention.
- FIG. 6 is a graph showing the neutral j3-dalcosidase inhibitory activity of the substances B-2 to 7 of the present invention.
- A- 2 of 1 H - is a diagram showing a chart of employment R. BEST MODE FOR CARRYING OUT THE INVENTION
- a starting material (Methyl -'- D-glucopyranoside, manufactured by Sigma) (10 g, 51.493 mmol) was dissolved in dimethylformamide (150 mL), and then imidazole (3.856 g,
- benzaldehyde dodimethinoreacetanol (36.3 mL, dimethylformamide solution of compound 14 (37.48 g, 186 ramol) was added (700 mL).
- the solvent was distilled off from the reaction solution under reduced pressure, and the obtained residue was dissolved in ethyl acetate, washed sequentially with saturated aqueous sodium hydrogen carbonate and saturated brine, and the obtained organic layer was dried over magnesium sulfate. Distilled off.
- reaction solution was diluted with ethyl acetate, saturated aqueous sodium bicarbonate was added, and the mixture was stirred.
- the organic layer was washed successively with saturated aqueous sodium bicarbonate and saturated saline, and then washed with magnesium sulfate. After drying with a steam, the solvent was distilled off under reduced pressure.
- the reaction solution was diluted with getyl ether, saturated aqueous sodium bicarbonate was added, and the mixture was stirred.
- the organic layer was washed successively with saturated aqueous sodium bicarbonate and saturated saline, dried over magnesium sulfate, and distilled under reduced pressure to remove the solvent. I left.
- the compound 29-6 (111.6 mg, 71.5%) was obtained.
- Compound 25-5 (15. Orag, 0.0404 mmol) was suspended in 10 mL of water, mixed with 0.5 mL of concentrated hydrochloric acid, and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- Compound 25-7 (13.5 mg, 0.0279 ol) was suspended in lOraL of water, mixed with 0.5 mL of concentrated hydrochloric acid, and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- Compound 30-1 (15 rag, 0.0649 mraol) was turbidized in 10 mL of water, and then mixed with 0.5 mL of concentrated hydrochloric acid and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water, lyophilized, and the substance B—1
- Compound 30-2 (22.4 mg, 0.0780raraol) was suspended in 8 raL of water, mixed with 1.0 ml of concentrated hydrochloric acid, and stirred for 1 hour. Then 50. After evaporating with C, ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- Compound 30-4 (15 mg, 0.0437 ol) was suspended in 10 mL of water, mixed with 0.5 raL of concentrated hydrochloric acid, and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- Compound 30-5 (15 mg, 0.0404 ol) was suspended in 10 mL of water, mixed with 0.5 mL of concentrated hydrochloric acid, and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- Compound 30-6 (15 rag, 0.0351 mmol) was suspended in 10 mL of water, mixed with 0.5 mL of concentrated hydrochloric acid, and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- Compound 30-7 (I5 mg, 0.0310 mmol) was suspended in 10 mL of water, mixed with 0.5 mL of concentrated hydrochloric acid, and stirred for 1 hour. Thereafter, the mixture was evaporated at 50 ° C, and ethanol and toluene were added and azeotroped three times. The residue is dissolved in water and freeze-dried.
- PH7.3 bovine liver-derived i3-D-galactosidase
- FIG. 2 shows the results for the substances A-2 to 7 of the present invention
- FIG. 3 shows the results for B-2 to 7.
- IC 5 value was calculated from the inhibition curve, which was the concentration of the inventive substance that decreased the concentration of 4-methylumberifuron when each inventive substance was not added.
- the substance of the present invention dissolved in water for injection, to which DMS0 had been added and dissolved if necessary.
- 25 ⁇ L of 0.2 ⁇ acetate buffer ( ⁇ 4.4) of bovine testis-derived ⁇ -D-galactosidase manufactured by Sigma
- 4-methyldumberipheryl- ⁇ -D-galactoate was used as a fluorescent substrate.
- FIG. 5 shows the results of substances A-2 to 7 of the present invention
- FIG. 6 shows the results of substances B-2 to 7.
- the 50% inhibitory concentration (IC 5 value) was calculated from the inhibition curve, which was the concentration of the inventive substance at which the 4-methylmberberry ferone concentration without addition of each inventive substance was reduced by 50%. Table 5 shows the results.
- novel acid addition salt of a carbasaccharide amine derivative having an inhibitory activity on galactosidase or] 3-dalcosidase and having improved power, solubility and solubility can be used for excellent treatment or prevention of glycolipid metabolism disorders based on the J3-galactosidase or ⁇ -dalcosidase gene.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04745313A EP1632476B1 (en) | 2003-05-19 | 2004-05-19 | Acid addition salt of carbasugar amine derivative |
US10/557,851 US7485755B2 (en) | 2003-05-19 | 2004-05-19 | Acid addition salt of carbasugar amine derivative |
JP2005506298A JP4602249B2 (ja) | 2003-05-19 | 2004-05-19 | カルバ糖アミン誘導体の酸付加塩 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-140868 | 2003-05-19 | ||
JP2003140868 | 2003-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004101493A1 true WO2004101493A1 (ja) | 2004-11-25 |
Family
ID=33447419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007138 WO2004101493A1 (ja) | 2003-05-19 | 2004-05-19 | カルバ糖アミン誘導体の酸付加塩 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7485755B2 (ja) |
EP (1) | EP1632476B1 (ja) |
JP (1) | JP4602249B2 (ja) |
WO (1) | WO2004101493A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011078302A1 (ja) | 2009-12-24 | 2011-06-30 | 生化学工業株式会社 | N-アルキル-β-バリエナミン類縁体の製造方法 |
JP2012158523A (ja) * | 2011-01-28 | 2012-08-23 | Hokko Chem Ind Co Ltd | 新規カルバ糖前駆体とそれらの製造方法、およびそれらを用いた生理活性カルバ糖アミン誘導体の製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60239000D1 (de) * | 2001-09-07 | 2011-03-03 | Seikagaku Kogyo Co Ltd | Carbazuckeraminderivate und mittel gegen störungenff enthalten |
TW201136904A (en) * | 2010-04-30 | 2011-11-01 | Nat Univ Tsing Hua | Method for preparing 2-morpholinoisobornane-10-thiol and intermediates formed therein |
CN102234255B (zh) * | 2010-05-07 | 2013-05-08 | 国立清华大学 | 2-吗啉基异嵌烷-10-硫醇的制备方法及其所形成的中间物 |
CN114751845B (zh) * | 2022-06-13 | 2022-09-20 | 北京君德同创生物技术股份有限公司 | 一种易溶的胍基乙酸络合物的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5764648A (en) * | 1980-10-06 | 1982-04-19 | Takeda Chem Ind Ltd | N-substituted derivative of valienamine, its preparation, and alpha-glucosidase inhibitor |
WO1996039412A1 (en) * | 1995-06-06 | 1996-12-12 | Alberta Research Council | Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5759813A (en) * | 1980-09-29 | 1982-04-10 | Takeda Chem Ind Ltd | Alpha-glucosidase inhibitor |
DE60239000D1 (de) | 2001-09-07 | 2011-03-03 | Seikagaku Kogyo Co Ltd | Carbazuckeraminderivate und mittel gegen störungenff enthalten |
-
2004
- 2004-05-19 US US10/557,851 patent/US7485755B2/en not_active Expired - Fee Related
- 2004-05-19 WO PCT/JP2004/007138 patent/WO2004101493A1/ja active Application Filing
- 2004-05-19 JP JP2005506298A patent/JP4602249B2/ja not_active Expired - Fee Related
- 2004-05-19 EP EP04745313A patent/EP1632476B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5764648A (en) * | 1980-10-06 | 1982-04-19 | Takeda Chem Ind Ltd | N-substituted derivative of valienamine, its preparation, and alpha-glucosidase inhibitor |
WO1996039412A1 (en) * | 1995-06-06 | 1996-12-12 | Alberta Research Council | Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising from exposure to an antigen |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011078302A1 (ja) | 2009-12-24 | 2011-06-30 | 生化学工業株式会社 | N-アルキル-β-バリエナミン類縁体の製造方法 |
JP2012158523A (ja) * | 2011-01-28 | 2012-08-23 | Hokko Chem Ind Co Ltd | 新規カルバ糖前駆体とそれらの製造方法、およびそれらを用いた生理活性カルバ糖アミン誘導体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1632476A4 (en) | 2007-05-16 |
JP4602249B2 (ja) | 2010-12-22 |
US20070010585A1 (en) | 2007-01-11 |
JPWO2004101493A1 (ja) | 2006-07-13 |
EP1632476A1 (en) | 2006-03-08 |
EP1632476B1 (en) | 2013-01-02 |
US7485755B2 (en) | 2009-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Benltifa et al. | 1, 3-Dipolar cycloaddition reactions on carbohydrate-based templates: synthesis of spiro-isoxazolines and 1, 2, 4-oxadiazoles as glycogen phosphorylase inhibitors | |
EP2661440B1 (en) | Method for the preparation of glycosphingolipids | |
RU2603769C2 (ru) | Семейство арил, гетероарил, о-арил и о-гетероарил карбасахаров | |
EP3052500B1 (fr) | Inhibiteurs de 5'-nucléotidases et leurs utilisations thérapeutiques | |
KR20010112354A (ko) | Impdh 효소의 억제제 | |
JP5976322B2 (ja) | テトラヒドロ−イミダゾ[1,5−a]ピラジン誘導体塩、その製造方法及び医薬用途 | |
JP2012519193A5 (ja) | ||
CN103781472A (zh) | 丙泊酚苷衍生物的合成和使用 | |
Bokor et al. | C-(2-Deoxy-d-arabino-hex-1-enopyranosyl)-oxadiazoles: synthesis of possible isomers and their evaluation as glycogen phosphorylase inhibitors | |
JP2018528211A (ja) | アミノグリコシド誘導体および遺伝性疾患の治療におけるその使用 | |
WO2004101493A1 (ja) | カルバ糖アミン誘導体の酸付加塩 | |
Thonhofer et al. | 5-Fluoro derivatives of 4-epi-isofagomine as d-galactosidase inhibitors and potential pharmacological chaperones for GM1-gangliosidosis as well as Fabry's disease | |
JP4233262B2 (ja) | カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤 | |
JP2020515527A (ja) | 置換イミダゾール塩系化合物、その調製方法、医薬組成物およびその応用 | |
EP4163287A1 (en) | A class of aryl glucoside derivatives, preparation method therefor and application thereof | |
Peng et al. | Targeting the tumor microenvironment by an enzyme-responsive prodrug of tubulin destabilizer for triple-negative breast cancer therapy with high safety | |
CA3173458A1 (fr) | Nouveaux composes chaperons pharmacologiques de l'alpha-glucosidase acide humaine et leur utilisation therapeutique | |
EP2041153B1 (fr) | Nouveaux derives de 5-thioxylopyranose | |
JP5082099B2 (ja) | アミロイドβ蛋白凝集制御剤 | |
Vega-Pérez et al. | Stereoselective synthesis of oxiranes as a source of isoserine analogues using d-glucosamine and d-glucose derivatives as chiral templates | |
EP4119550A1 (en) | Aryl glucoside derivative and use thereof in drug | |
JP5034039B2 (ja) | Gm3類似体 | |
FR2860234A1 (fr) | Nouveaux derives 666 du thioxylose | |
EP4166547A1 (en) | Aryl glucoside derivative | |
KR101356945B1 (ko) | 세이마토스포리움 디스코시오이데스에서 분리된 신규 폴리하이드록실레이티드 마크로라이드 유도체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506298 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007010585 Country of ref document: US Ref document number: 10557851 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004745313 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004745313 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10557851 Country of ref document: US |